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Abstract
Background: The 23-valent polysaccharide pneumococcal vaccine (PPV-23) is recommended for elderly and high-
risk people, although its effectiveness is controversial. Some studies have reported an increasing risk of acute
vascular events among patients with pneumonia, and a recent case-control study has reported a reduction in the
risk of myocardial infarction among patients vaccinated with PPV-23. Given that animal experiments have shown
that pneumococcal vaccination reduces the extent of atherosclerotic lesions, it has been hypothesized that PPV-23
could protect against acute vascular events by an indirect effect preventing pneumonia or by a direct effect on
oxidized low-density lipoproteins. The main objective of this study is to evaluate the clinical effectiveness of PPV-23
in reducing the risk of pneumonia and acute vascular events (related or nonrelated with prior pneumonia) in the
general population over 60 years.
Methods/Design: Cohort study including 27,000 individuals 60 years or older assigned to nine Primary Care
Centers in the region of Tarragona, Spain. According to the reception of PPV-23 before the start of the study, the
study population will be divided into vaccinated and nonvaccinated groups, which will be followed during a
consecutive 30-month period. Primary Care and Hospitals discharge databases will initially be used to identify study
events (community-acquired pneumonia, hospitalisation for acute myocardial infarction and stroke), but all cases
will be further validated by checking clinical records. Multivariable Cox regression analyses estimating hazard ratios
(adjusted for age, sex and comorbidities) will be used to estimate vaccine effectiveness.
Discussion: The results of the study will contribute to clarify the controversial effect of the PPV-23 in preventing
community-acquired pneumonia and they will be critical in determining the posible role of pneumococcal
vaccination in cardiovascular prevention.
Background
Epidemiology of pneumococcal infections
Infections caused by Streptococcus pneumoniae remain a
major public health problem throughout the world. Sus-
ceptibility to pneumococcal infections varies with age,
being highest in young children and older adults, who
experience substantial morbidity and mortality
(especially in those with underlying high-risk medical
conditions) [1,2].
The main reservoir of pneumococcus is the nasophar-
ynx, and the possible outcomes after colonisation are
the clearance by the organism, the asymptomatic persis-
tence for several months (carrier state), or the progres-
sion to disease. During the disease the bacteria can
spread to adjacent mucosal tissues causing mucosal
infections (otitis, sinusitis, bronchitis and pneumonias)
or it can invade the bloodstream, or other sterile sites,
producing an invasive pneumococcal disease (IPD). In
adults, S. pneumoniae is the most frequent isolate from
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responsible for approximately 50% of overall cases of
community-acquired pneumonia (CAP) in different
populations [3-5].
Pneumococcal vaccination
In the last decades, the need for preventive strategies
has driven multiple efforts to develop an effective vac-
cine, however the existence of more than 90 distinct
pneumococcal serotypes has largely complicated the
development and evaluation of anti-pneumococcal vac-
cines. To date, only a 23-valent polysaccharide pneumo-
coccal vaccine (PPV-23) for use in adults and a 7-valent
conjugate vaccine for use in infants are available in clini-
cal practice [6-9].
The PPV-23 is generally recommended for high-risk
and elderly individuals, but its effectiveness (despite
numerous meta-analyses) remains controversial [10-19].
It has been demonstrated that PPV-23 provides consid-
erable protection against invasive pneumococcal disease,
while a possible protective effect against pneumonia is
discussed [20]. The latest Cochrane Systematic Review
supports the use of PPV to prevent IPD in adults, parti-
cularly in healthy adults, but it concluded that the meta-
analysis does not provide compelling evidence to sup-
port the routine use of PPV to prevent pneumonia [18].
Epidemiological link between pneumonia and acute
vascular events
For several decades, there has been data that chronic
inflamation can promote atherosclerotic disease,[21] and
in recent years some studies have also found data sup-
porting the fact that acute infections (especially influ-
enza and pneumonia) are associated with a transient
increasing risk of acute vascular events [22-25]. In fact,
it has been reported that a combination of the diagnosis
of pneumonia and myocardial infarction is relatively
common among patients hospitalised with severe pneu-
monia [24,25]. Thus, given this data, it has been sug-
gested that pneumococcal vaccination could perhaps
protect patients from cardiovascular events [26-28].
Following this, a recent case-control study conducted
in Canada has reported a 47% reduction in the risk of
acute myocardial infarction (AMI) among subjects who
had received the PPV-23, however, the posible cardio-
protective effect of pneumococcal vaccination has not
still been proved [26].
Theoretically, pneumococcal vaccination could protect
against acute cardiovascular events by an indirect effect
preventing pneumonia (as the latter has been shown to
trigger myocardial infarction), although a direct effect of
pneumococcal vaccination on oxidized low- density lipo-
proteins can not be excluded. In fact, animal experi-
ments have shown that pneumococcal vaccination
reduces the extent of atherosclerotic lesions and it has
been hypothesized that antibodies directed against
Streptococcus pneumoniae would also recognize oxi-
dized low-density lipoprotein and impede the formation
of foam cells [29].
The posible effectiveness of PPV-23 to prevent myo-
cardial infarction, if it exists, probably has been overesti-
mated in the aforementioned Canadian report; however,
given the prevalence of heart disease worldwide, even a
modest protective effect (epidemiologically plausible)
would translate into a considerable benefit at the popu-
lation level [30]. Thus, prospective validations (which
will determine whether the cardioprotective effect of
vaccination is real and better estimate its true protective
efficacy) are greatly needed.
Use of pneumococcal vaccine in the study area
In Catalonia, a region in the northeast of Spain with a
population of seven million people, a publicly funded
anti-pneumococcal vaccination programme for all indi-
viduals 65 years or older (with or without risk factors)
and younger individuals with certain high-risk condi-
tions (basically immunodeficiency, chronic heart or pul-
monary disease, diabetes mellitus, severe liver disease or
chronic nephropathy) began in October 1999. Further, it
was extended for all people 60 years or older in 2002.
S i n c et h e n ,af r e eP P V - 2 3h a sb e e no f f e r e dw h e nt h e
patients came to the primary care services during the
annual influenza vaccination campaigns or in any other
visit throughout the year. Some years later, vaccination
uptake reached approximately fifty percent,[31] and this
provided an excellent opportunity to evaluate the vac-
cine’s effects among the population. The potential
effects of vaccination in preventing IPD and pneumonia
have been analyzed in our reference population in two
prior studies [32,33].
This project proposes a large population-based cohort
study with the major aim of evaluating the clinical effec-
tiveness of the PPV-23 against CAP as well as evaluating
its potential role in cardiovascular prevention among the
general population over 60 years.
Objectives of the capamis study
The primary objective of the planned study entitled
CAPAMIS is to evaluate the clinical effectiveness of the
PPV-23 in the prevention of a first episode of Commu-
nity-Acquired Pneumonia, Acute Myocardial Infarction
and Stroke among the general population over 60 years.
Furthermore, the study will evaluate the effectiveness of
PPV-23 in reducing the risk of secondary acute vascular
events related with prior pneumonia.
Additional objectives include the evaluation of vacci-
nation effectiveness against severity outcomes (including
death, need of ICU admission or length of stay in
hospital).
Furthermore, a detailed analysis on population-based
data on incidence of myocardial infarction and stroke
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with certain underlying conditions in order to establish,
if it exists, the magnitude of vaccination effectiveness in
primary and/or secondary cardiovascular prevention.
In addition to these objectives, the clinical effective-
ness of revaccination against different outcomes will be
evaluated in the subset of participants who have
received more than a dose of PPV-23 prior to the study
start or during the study period.
Methods and Design
Design, setting and study population
Population-based cohort study focused on adults over
60 years in the region of Tarragona, a mixed residential-
industrial urban area in the Mediterranean coast of Cat-
alonia, Spain.
Study subjects include 27,000 community-dwelling
adults aged 60 years or more assigned to 9 participating
Primary Care Centres (PCCs) in the study area, who will
followed during a 30-month consecutive period. Six of
the nine participating PCCs are located in Tarragona
city (PCC Bonavista, PCC Torreforta, PCC Jaume I,
PCC Sant Pere i Sant Pau, PCC Tarraco, PCC Sant Sal-
vador) and three PCCs are located in nearby (less than
12 kilometres from Tarragona) smaller municipalities
(PCC Salou, PCC Constanti and PCC Morell). Two
reference hospitals for the study population are Hospital
Joan XXIII and Hospital Santa Tecla, both located in
Tarragona city (which has an overall population of
approximately 120,000 all-age inhabitants).
It must be noted that, in Spain, primary care physi-
cians are the first point of call for secondary and tertiary
care and all citizens are registered in one PCC.
Inclusion criteria for the CAPAMIS cohort include: a)
male or female adults aged 60 years or older as of Janu-
a r y1 ,2 0 0 9 ;a n db )r e g i s t e r e di na n yo ft h en i n eP C C s
participating at study start. Exclusion criteria include
residence in a long-term care facility. Subjects will be
identified from primary care information systems. Figure
1 shows the study region and illustrates the location of
participating centres.
Cohort members will be followed from the beginning
of the study (1 January 2009) until occurrence of the
first event, the enrolment from the PCC ceases, death,
or until the end of the study (30 June 2011).
Rationale for sample size
The annual incidence of CAP in older adults in the
study area is estimated at approximately 10 per 1000
person-year based on prior population-based studies
among elderly people in the same study area [34,35].
Incidences of AMI and stroke are estimated in 8 and 12
cases per 1000, respectively, in Spanish population
[36,37]. Thus, considering a pneumococcal vaccine cov-
erage of approximately 50%,[31] with a p = 0.05 (two-
tailed) the size of the study cohort (N = 27,000 indivi-
duals followed during a 30-month period) has an statis-
tical power of 80% to detect a posible vaccination
effectiveness of 20% against CAP, a 23% against AMI, a
18% against stroke and a 14% against the combined
end-point AMI/stroke.
Data sources
All participating PCCs haveac o m p u t e r i z e dc l i n i c a l
record system that includes administrative data, medical
conditions, prescriptions, laboratory results and regis-
tries associated with outpatient visits and diagnoses
coded according to the International Classification of
Diseases, 10th Revision (ICD-10). This electronic clinical
record system will be used to classify vaccination status
as well as to identify comorbidities or underlying condi-
tions in cohort members and establish baseline charac-
teristics of the cohort at study start.
During the study period, the primary care electronic
registries of the nine participating PCCs will be used as
ad a t as o u r c et oi d e n t i f yt h o s es u b j e c t sw h oh a v es u f -
fered any study event that did not require hospitalisation
and were treated as an outpatient during the 30-month
study period.
Emergence and hospital diagnosis discharge databases
of two reference hospitals (coded according to ICD-9-
CM codes (International Classification of Diseases, 9th
Revision, Clinical Modification) will be used to identify
those cohort members who were admitted to hospital
for any study event during the 30-month study period.
A structured data collection instrument will be used
to review primary care and hospital clinical records to
validate the diagnosis of all cases initially identified by
ICD-10 or ICD-9 discharge codes.
Main outcomes and definitions
The primary endpoints of the CAPAMIS Study will be
the ocurrence of CAP (hospitalised or outpatient), hos-
pitalisation for AMI, stroke and death from any cause.
Table 1 shows definitions and criteria used in collecting
primary and secondary outcomes.
The occurrence of CAP will be established on the
basis of an acute respiratory illness, with evidence of the
presence of a new infiltrate in a chest radiograph.
Outpatient CAP will be identified from primary care
or emergency visit (not hospitalised) with a code regis-
tered for pneumonia in the PCCs diagnoses databases
(ICD-10 codes: J10.9, J11.9, J12 to J18) or in Emergency
discharge databases (ICD-9-CM codes: 480 to 487.0).
Hospitalisations for CAP will be identified on the basis
of the listed primary diagnosis codes in the hospital dis-
charge databases (ICD-9-CM codes 480 to 487.0).
All cases of CAP (hospitalised and outpatient) must be
radiographically confirmed and validated by checking the
clinical record with the use of a standardized data-collec-
tion instrument (which includes sociodemographical,
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the time of diagnosis). CAP will be considered if, on con-
clusion of the medical record review, the physician
reviewer verified this diagnosis and it was not a readmis-
sion, a nosocomial pneumonia or another diagnosis.
Pneumonia severity index (PSI) and the simpler severity
rule CURB-65 will be calculated according to criteria
described in classical studies [38,39].
Hospitalisation for AMI will be initially identified on
the basis of listed primary and secondary diagnosis
codes in the reference hospital discharge database (ICD-
9-CM code: 410).
Hospitalisation for stroke will also be initially identi-
fied on the basis of the listed primary and secondary
diagnosis codes in hospital discharge databases (ICD-9-
CM codes 430 to 437). Ischaemic strokes (codes 433,
434, 436 or 437) and hemorrhagic strokes (codes 430 to
432) will be considered, but transient ischemic attacks
(code 435) will be excluded for the analyses.
All cases of AMI and stroke will be further validated
by checking hospital medical records with a standar-
dized data-collection instrument that includes clinical
characteristics of the events, and they will be classified
as “CAP-related” (occurring within 30 days after onset
of pneumonia) or “CAP-nonrelated” (ocurring more
than 30 days after an episode of pneumonia or ocur-
ring among patients who have not suffered a previous
CAP).
Figure 1 Research areas of the CAPAMIS Study. This figure illustrates the geographical distribution of the nine participating Primary Health
Care Centers in the region of Tarragona (a mixed residential-industrial urban area, which is located 95 Km from Barcelona, in the mediterranean
coast of Catalonia, Spain).
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study participants is not feasible. Nevertheless, the nine
PCCs and two reference hospitals provide daily care to
the inhabitants living in the selected study area, and they
basically apply similar diagnostic checklist and treatment
for patients presenting with a clinical suspicion of pneu-
monia, myocardial infarction or cerebrovascular accident.
Vaccination history
Vaccination status of cohort members will be deter-
m i n e db yar e v i e wo ft h eP C C s ’ electronic clinical
records, which contain specially designated fields for
pneumococcal and influenza vaccinations. We assume
that information in clinical records is complete, so a
subject will be considered as unvaccinated when a vacci-
nation was not recorded in the PCC clinical record.
Pneumococcal vaccination status (including number of
dose of PPV-23 received in prior 10 years) will be deter-
mined at study start and it will be reevaluated at the
end of the first and second year of the study period.
Similarly, influenza vaccination status will be determined
Table 1 Definitions and criteria used to identify and classify the different endpoints in the CAPAMIS Study.
OUTCOMES DEFINITIONS
A. Community-acquired
pneumonia (CAP)*
Pneumonia will be considered when a new radiological infiltrate is identified in a patient with one major
criterion (cough, expectoration or fever) or two minor criteria (dyspnea, pleuritic pain, altered mental status,
pulmonary consolidation on auscultation and leukocytosis).
A1. Hospitalised CAP Will be considered those pneumonia cases identified on the basis of the listed primary diagnosis codes in
hospital discharge databases (ICD-9-CM codes for pneumonia: 480 to 487.0).
A2. Outpatient CAP Will be considered those CAP cases non-hospitalised, and they will be identified from primary care or emergency
visits (not hospitalised) with a code registered for pneumonia in the Emergency Unit discharge codes databases
(ICD-9-CM codes: 480 to 487.0) or Primary Care Centers diagnosis database (ICD-10 codes: J10.9, J11.9 and J12 to
J18).
B. Pneumococcal CAP** Defined as a patient with CAP from whom Streptococcus Pneumoniae is identified by blood culture, sputum
culture or urinary antigen.
B1. Bacteremic pneumococcal
CAP
Will be considered when S. pneumoniae was isolated from blood specimens or other sterile sites.
B2. Nonbacteremic
pneumococcal CAP
Will be considered when the patients have a typical clinical syndrome of pneumonia without bacteremia
(negative or not performed blood culture), but they have a sputum culture that yielded pneumococci with no
other likely bacterial pathogens and/or they have positive Binax-NOW Streptococcus pneumoniae urinary antigen
test.
C. Acute myocardial infarction
(AMI)
Defined as a patient hospitalised with diagnosis of acute or recurrent episode of myocardial infarction. Cases will
be identified on the basis of the primary and secondary listed diagnosis codes in the hospital discharge database
(ICD-9-CM code for AMI: 410). All initially identified cases of AMI will be further validated by checking hospital
medical records, and each case will be classified as related or nonrelated with a prior episode of CAP.
C1. CAP-related episode of
AMI
Defined as AMI ocurring within the first 30 days after the onset of an episode of CAP.
C2. CAP-nonrelated episode of
AMI
Case of AMI ocurring more than 30 days after an episode of CAP or in a patient without history of prior CAP.
D. Hospitalisation for stroke Defined as a patient admitted to hospital with a diagnosis of stroke, ictus or cerebral infarction. Cases will be
identified on the basis of the primary and secondary listed diagnosis codes in the hospital discharge databases
(ICD-9-CM codes for stroke: 430 to 437). Haemorragic strokes (codes 430 to 432) and ischaemic strokes will be
considered (codes 433, 434, 436 or 437), but transient ischaemic attacks (code 435) will be excluded for the
analyses. All cases initially identified of stroke will be further validated by checking hospital medical records, and
each case will be classified as related or nonrelated with a prior episode of CAP.
D1. CAP-related episode of
stroke
Defined as an episode of stroke ocurring within the first 30 days after the onset of CAP.
D2. CAP-nonrelated episode
of stroke
Defined as an episode of stroke ocurring more than 30 days after an episode of CAP or in a patient without
history of a prior episode of CAP.
E. All-cause death It includes patients who died for any cause during the study period. Cases will be identified from primary care
information system of each participating PCC.
E1. Death from CAP Defined as a patient who died (in hospital or not) within the first 30-days after the onset of CAP.
E2. Death from AMI Defined as a patient who died within hospital stay or within the first 30-days after the diagnosis of AMI.
E3. Death from stroke Defined as a patient who died within hospital stay or within the first 30 days after the onset of the stroke.
* All cases of CAP (hospitalised and outpatient) must be radiographically confirmed and validated by checking the clinical record with the use of a standardized
data-collection instrument. CAP will be considered if, on conclusion of the medical record review, the physician reviewer verified this diagnosis and it was not a
readmission, nosocomial pneumonia or another diagnosis.
** Pneumococcal CAP will initially be identified on the basis of ICD-9-CM codes for pneumococcal bacteraemia (codes 038.0, 038.2, 041.0, 041.2) or pneumococcal
pneumonia (code 481) in the Hospitals and Emergency discharge diagnosis databases and ICD-10 code for pneumococcal pneumonia (code J13) in the Primary
Care visits diagnosis databases. Laboratory records will also be used to identify cases of pneumococcal infections not detected in ICD-9-CM or ICD-10 discharge
codes.
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not of a dose of flu vaccine in prior autumn) and it will
also be reevaluated every year of the study period.
Covariates
Covariates will be age, sex, frequency of attendance
(number of outpatient visits per year), history of pneu-
monia in 24-month before study start, history of coron-
ary artery disease, history of prior stroke, presence of
major cardiovascular risk factors (hypertension, hyperch-
olesterolaemia, smoking, diabetes mellitus or obesity),
presence of major comorbidities (chronic heart disease,
chronic pulmonary disease, severe liver disease, chronic
nephropathy or cancer) and immunological status. Table
2 lists covariates and shows criteria used to measure
and capture underlying conditions and comorbidities in
the study cohort.
Statistical analysis
Absolute numbers, means and percentages will be com-
puted to describe the patient population. The differences
between groups will be evaluated using the chi-squared
or Fisher’s test for categorical variables, and the two
tailed Student’s test or ANOVA for continuous variables
as appropriate.
The crude association between the outcomes and vac-
cination will be evaluated using incidence rates among
vaccinated and unvaccinated subjects. The incidence of
each event will be calculated as person-year considering
in the denominator the sum of person-time contributed
to each individual during study period.
Multivariable Cox proportional hazards models with
time-varying covariates will be used to calculate hazards
ratio (HR) and estimate the association between having
received the pneumococcal vaccine and the time of the
first outcome event during the study period. Repeated
episodes will not be included in the analyses. Vaccine
effectiveness will be estimated as (1 - HR) × 100.
Pneumococcal vaccination status will be a time-vary-
ing condition (e.g., individuals vaccinated after the
beginning of the study) and persons will be considered
to be vaccinated 14 days after vaccine administration.
Annual influenza vaccine status will also be a time-vary-
ing covariate, whereas the other covariates will be
defined at study start.
It will be checked for confounders, interactions and
multicollinearity among the independent variables. The
final models will be adjusted by all significant variables,
as well as confounders and other baseline covariables
judged of having clinical importance. The proportional
hazards assumptions will be assessed adding the covari-
a t eb yl o g - t i m ei n t e r a c t i o n st ot h em o d e la n dp l o t t i n g
the scaled and smoothed Schoenfeld residuals obtained
Table 2 Definitions and criteria used to collect
respiratory and cardiovascular risk factors and main
comorbidities among cohort members in the CAPAMIS
Study.*
UNDERLYING
CONDITIONS
DEFINITIONS
History of prior
pneumonia
Includes influenza-related pneumonia (J10.0
and J11.0), viral pneumonia (J12),
pneumococcal pneumonia (J13), pneumonia
due to Haemophillus influenzae (J14), bacterial
pneumonia (J15), pneumonia due to other
infectious organisms (J16), pneumonia in
diseases classified elsewhere (J17) and
pneumonia due to unspecified
microorganisms (J18).
History of coronary
artery disease
Includes angina (I20), acute myocardial
infarction (I21), subsequent or recurrent
myocardial infarction (I22) and chronic
ischaemic heart disease (I25).
History of stroke Includes haemorrhagic stroke (I60 to I62),
cerebral infarction (I63) and stroke not
specified as haemorrhage or infarction (I64); it
does not include transient ischaemic attacks
(code G45).
Hypertension Defined as the presence of any code I10, I11,
I12, I13 or I15.
Hypercholesterolemia Defined as the presence of code E78.
Diabetes mellitus Codes E10 to E14.
Obesity Patients with registered code E66 (BMI>30%).
Smoking Includes patients with current smoking (code
F17 active at study start).
Alcoholism Includes patients with code F10 active at study
start.
History of heart
disease
Includes congestive heart failure (I50),
hypertensive heart disease (I11),
cardiomyopathy (I42), cardiac dilatation or
ventricular hypertrophy (I11.9 or I51.7) and
coronary artery disease (I20, I21, I22 and I25).
History of vascular
ischaemia
Besides coronary artery disease and stroke, it
Includes atheroesclerosis (I70), acute arterial
embolism or thrombosis (I74) and peripheric
arterial disease or intermittent claudication
(I73.9).
Chronic pulmonary
disease
Includes chronic bronchitis or emphysema (J42
to J44) and asthma: (J45).
Severe liver disease Includes chronic viral hepatitis (B18), alcoholic
hepatitis (K70) and cirrhosis (K74).
Severe nephropathy Includes nephrotic syndrome (N04 or N39.1),
renal failure (N18, N19) and kidney dialysis
(Y84.1) or transplantation.
Immunocompromise Defined as the presence of any
immunodeficiency (D80 to D84), AIDS (B20 to
B24), anatomic or functional asplenia (D73.0
and Q89.0), cancer, severe nephropaty, or
long-term corticosteroid therapy (20 mg/day
of prednisone or equivalent).
* Data will be considered at the beginning of the study, and it will be defined
according to the International Classification of Diseases 10th Revision (ICD-10)
codes registered in the primary care clinical record of each cohort member at
the start of the study.
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significance will be set at p < 0.05 (two-tailed). The ana-
lyses will be performed using Stata/SE Version 9.1.
(Stata Corp.)
Ethical concerns
The study protocol has received ethics approval by the
ethical committee of clinical research of the IDIAP Jordi
Gol Foundation of the Catalonian Health Institute (ID
P09/49) and it will be conducted in accordance with the
general principles for observational studies.
The study protocol has received ethics approval by the
ethical committee of Catalonian Health Institute (ID:
CEIC IDIAP J. Gol P09/49) and it will be conducted in
accordance with the general principles for observational
studies. Given this is a non-interventional study, an
informed consent for all 27000 study participants will
not be required, but consent will be obtained to rewiev
clinical records of those cohort members who suffer any
study event during follow-up.
Discussion
The clinical effectiveness of the PPV-23 is controversial,
especially in preventing some outcomes such as CAP or
AMI. However, given the demonstrated effectiveness of
the vaccine in protecting individuals against IPD, com-
mencing new randomised clinical trials in populations at
risk where vaccine effectiveness and disease burden is
known would create ethical difficulties. Thus, cohort
studies are an acceptable alternative to estimate vaccine
effectiveness against different pneumococcal-related out-
comes among different populations at risk.
To our knowledge, this population-based cohort study
in adults aged 60 years or older is the first large pro-
spective study planed to evaluate the possible clinical
effectiveness of pneumococcal vaccination against acute
myocardial infarction and stroke, related or not with
prior episodes of pneumonia.
The results of the study will contribute to clarify the
controversial effect of the PPV-23 in preventing com-
munity-acquired pneumonia and they will be important
to determine the possible role of pneumococcal vaccina-
tion in cardiovascular prevention.
This study has been conceived and designed to investi-
gate the clinical effectiveness of the PPV-23 against pneu-
monia and acute cardiovascular events. Nevertheless, in
addition to the primary objectives of the study, several
substudy objectives are currently under development to
maximise opportunities to learn about the health condi-
tions in this older adult population-based cohort.
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